CatSci, a fast growing and adaptable contract research organisation (CRO) based in Cardiff, has triumphed at the global CPhI Pharma Awards by winning the prestigious Excellence in Pharma: Contract Services and Outsourcing category. Receiving one of the most esteemed awards in the pharmaceutical industry reflects CatSci’s exceptional process research and development services.

CatSci has been recognised for its innovative use of biocatalysis to significantly improve the environmental and economical sustainability of a generic API. CatSci’s development of a novel manufacturing process addressed route inefficiencies and an impending patent expiration. The scope of this project reflects the substantial interest that biocatalysis is currently receiving from both industry and academia.

Throughout the project CatSci exemplified its ability to provide both technical and commercial solutions through a consultative approach. CatSci worked collaboratively with its customer to ensure that the project received funding from the UK government. CatSci also utilised its proven combination of commercially-minded and highly-qualified scientific expertise to ensure that the novel manufacturing route would receive a return on investment.

The Accelerated Growth Programme provided CatSci with strategy support, an application for external funding and commercial consultancy.

Founded in 2004, the CPhI Pharma Awards attract a prestigious range of global applicants. Nominees in this year’s Excellence in Pharma: Contract Services and Outsourcing category included Merck, Cambrex and Alcami.

Dr Ross Burn, Chief Executive Officer, CatSci, said: “We are ecstatic to have received this recognition from the CPhI Awards. This achievement is a fantastic stepping stone along our journey to becoming the leading process R&D company. Our category featured some exceptional nominees, so it truly is an honour to be considered alongside them for such a prestigious award.”

Further information on the Business Wales Accelerated Growth Programme.